IMOS:NASDAQChipMOS TECHNOLOGIES INC. Analysis
Data as of 2026-05-19 - not real-time
$51.40
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
ChipMOS Technologies (IMOS) is trading above its short‑term moving averages, indicating a bullish price bias, while the 14‑day RSI sits in the mid‑50s, suggesting limited upside momentum. The MACD shows a bearish divergence with the histogram turning negative, and the stock is approaching a well‑defined resistance level near the recent high, which could cap short‑term gains.
On the fundamentals side, the company posted strong revenue growth and maintains a healthy dividend yield, but the payout ratio is near 100%, free cash flow is negative, and debt levels are elevated relative to equity. Valuation metrics such as the price‑to‑earnings ratio are materially higher than the industry average, implying the market has priced in significant growth expectations that may be difficult to sustain without stronger cash generation.
On the fundamentals side, the company posted strong revenue growth and maintains a healthy dividend yield, but the payout ratio is near 100%, free cash flow is negative, and debt levels are elevated relative to equity. Valuation metrics such as the price‑to‑earnings ratio are materially higher than the industry average, implying the market has priced in significant growth expectations that may be difficult to sustain without stronger cash generation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price above short‑term SMA but MACD turning bearish
- Increasing volume supporting the current trend
- Proximity to resistance level may limit upside
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Robust revenue growth and dividend yield
- Elevated valuation relative to peers
- High debt load and negative free cash flow
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Long‑term demand for OSAT services in the semiconductor chain
- Sustained dividend despite cash flow concerns
- Geopolitical exposure and high beta increasing market risk
Key Metrics & Analysis
Financial Health
Revenue Growth25.40%
Profit Margin3.25%
P/E Ratio65.1
ROE3.33%
ROA2.19%
Debt/Equity64.29
P/B Ratio2.3
Op. Cash Flow$3.3B
Free Cash Flow$-231215008
Industry P/E38.2
Technical Analysis
TrendBullish
RSI54.4
Support$41.85
Resistance$61.27
MA 20$50.36
MA 50$43.73
MA 200$30.82
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61
Valuation
Fair Value$2,242.31
GradeOvervalued
TypeGrowth
Dividend Yield1.62%
Risk Assessment
Beta1.40
Volatility92.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.